Home / Clients / Assignments
Assignments

 Strategic Partnership Assignments:
 
current_strategic_partnership_assignments


New Market Entry Assignments:
 
Current product commercialization assignments

 


Accelerator Portfolio
Bio-Assets

BioAssets Development Corporation, a biopharmaceutical company, develops spine indications for biologic drugs. It focuses on the development of a tumor necrosis factor alpha (TNF) inhibitor therapy to treat the underlying cause of pain in sciatica. It markets tumor necrosis factor alpha (TNF) inhibitors, which include monoclonal antibodies, infliximab or adalimumab, TNF-receptor fusion protein etanercept, and biologic drugs for the treatment of inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, and psoriasis. The company’s lead program also tests the potential of TNF inhibitors to treat pain and prevent nerve damage in patients with spinal disorders by treating the neuro-inflammatory disease mechanism.  Cephalon exercised its option to acquire BDC in October 2011.

 

Janusbio therapeutics

Janus Biotherapeutics is developing a novel, orally available TLR 7/8/9 receptor antagonist for the treatment of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome and psoriasis.  There is widespread scientific consensus that TLRs or Toll-like receptors play an important role in the immune system and in aberrant immune responses.   By blocking these unwanted immune responses, a TLR 7/8/9 antagonist offers the promise of providing a novel therapy for a wide range of autoimmune diseases.
Web site: www.janusbio.com

 

Acer Therapeutics

Acer Therapeutics Inc.  is developing the first pharmaceutical therapy for patients with Maple Syrup Urine Disease (MSUD), a devastating genetic disease that results from an inborn error of amino acid metabolism. A randomized controlled double-blind Phase 2/3 clinical study of sodium phenylbutyrate (NaPBA) in MSUD is ongoing, and is expected to read out in 2H 2015. The company focuses on repurposing and reformulating existing therapeutics for orphan indications with unmet medical needs.
Web site: www.acertx.com

 

Dartmouth Medical

Dartmouth Medical Research Ltd. is a life sciences company based in Halifax, Nova Scotia. The company is developing a biomaterials solution for reconstructing traumatized bones to replace traditional plates and screws. Preclinical in vivo models have demonstrated that this solution takes less time in surgery and produces better healing.